Brilinta Loading Dose
The recommended loading dose of Brilinta (ticagrelor) is 180 mg administered orally, followed by the first 90 mg maintenance dose 6 to 12 hours after the loading dose 1, 2.
Clinical Context and Dosing
The 180 mg loading dose is consistently recommended across multiple clinical scenarios:
Acute Coronary Syndromes (NSTE-ACS and STEMI)
- Loading dose: 180 mg orally
- Maintenance: 90 mg twice daily for the first year after ACS
- After one year, may reduce to 60 mg twice daily 1, 2
Acute Ischemic Stroke or TIA
- Loading dose: 180 mg orally
- Maintenance: 90 mg twice daily for up to 30 days
- Administer first maintenance dose 6-12 hours after loading 2
Coronary Artery Disease (No Prior MI/Stroke)
- No loading dose in this population
- Start directly with 60 mg twice daily 2
Administration Considerations
Aspirin co-administration is critical: Use low-dose aspirin (75-100 mg daily) as maintenance therapy. Higher aspirin doses (>100 mg daily) may reduce ticagrelor effectiveness—this is a unique FDA black box warning specific to ticagrelor 1, 2.
For patients unable to swallow: Tablets can be crushed, mixed with water, and administered orally or via nasogastric tube (≥CH8) 2.
Timing matters: In ACS patients, administer the loading dose as soon as possible after presentation, regardless of whether invasive or conservative management is planned 1. Research demonstrates that ticagrelor pretreatment (before PCI) is superior to prasugrel given at the time of PCI for preventing periprocedural myonecrosis 3.
Key Clinical Pitfalls
Do not use with other P2Y12 inhibitors: Discontinue clopidogrel when starting ticagrelor 4, 2.
Contraindications to the loading dose:
- History of intracranial hemorrhage (absolute contraindication) 2
- Active pathological bleeding 2
- Known hypersensitivity to ticagrelor 2
Special populations:
- Patients with prior stroke/TIA should NOT receive prasugrel, but ticagrelor remains appropriate 1
- Avoid in severe hepatic impairment 2
- Use caution in patients with bradyarrhythmias or sick sinus syndrome 2
Evidence Strength
The 180 mg loading dose is supported by the highest level of evidence from the PLATO trial (18,624 patients), which demonstrated superiority over clopidogrel for reducing cardiovascular death, MI, and stroke (HR 0.84,95% CI 0.77-0.92, p=0.0003) 2. This dosing is consistently endorsed in the 2025 ACC/AHA guidelines 1, 2017 ESC guidelines 4, and FDA labeling 2.
The combination of 180 mg ticagrelor loading with low-dose aspirin (75-100 mg) represents the evidence-based standard for ACS management, with superior outcomes compared to clopidogrel and without increased major bleeding when aspirin is appropriately dosed 1, 5.